Abstract： Objective： To observe the clinical efficacy of Qihuang Shenduqing in the treatment of patients with stages 2-3 chronic kidney disease （CKD） of damp-turbidity （toxin） type. Methods：A total of 80 patients with stages 2-3 CKD of damp-turbidity （toxin） type admitted to Shenzhen Bao'an Traditional Chinese Medicine Hospital from January to November 2025 were enrolled and randomly divided into a trial group and a control group using the random number table method，with 40 cases in each group. Among them，4 cases dropped out from the trial group and 3 cases from the control group， resulting in 36 cases in the trial group and 37 cases in the control group， respectively. The control group received integrated CKD standard treatment， while the trial group received additional Qihuang Shenduqing on the basis of the control group's treatment. The treatment course lasted 12 weeks. The scores of traditional Chinese medicine syndrome， levels of serum creatinine （SCr）， blood urea nitrogen （BUN）， estimated glomerular filtration rate （eGFR），urinary albumin-to-creatinine ratio （UACR），and urinary β2-microglobulin （U-β2-MG），as well as clinical efficacy and incidence of adverse reactions were compared between the two groups. Results： After treatment，the total effective rate was 86.11%（ 31/36） in the trial group and 62.16%（ 23/37） in the control group，with a statistically significant difference between the two groups （P＜0.05）. After treatment， traditional Chinese medicine syndrome scores in both groups decreased compared with those before treatment （P＜0.05），and the score in the trial group was lower than that in the control group （P＜0.05）. After treatment， eGFR levels in both groups increased compared with those before treatment （P＜0.05）， and the eGFR level in the trial group was higher than that in the control group （P＜0.05）. After treatment，SCr and BUN levels in the trial group decreased compared with those before treatment （P＜0.05），and levels of both indicators were lower than those in the control group （P＜0.05）；SCr level in the control group decreased compared with that before treatment （P＜0.05）， but there was no statistically significant difference in BUN level in the control group before and after treatment （P＞0.05）. After treatment，UACR level in the trial group decreased compared with that before treatment（ P＜0.05），and was lower than that in the control group（ P＜ 0.05）； while there was no statistically significant difference in UACR level before and after treatment in the control group（ P＞0.05）. There was no statistically significant difference in U-β2-MG levels before and after treatment in either group （P＞0.05）. During treatment， the incidence of adverse reactions was 2.78% （1/36） in the trial group and 5.41% （2/37） in the control group， with no statistically significant difference between the two groups （P＞0.05）. Conclusion： Qihuang Shenduqing demonstrates certain efficacies in the treatment of stages 2-3 CKD of dampturbidity （toxin） type，which can improve clinical symptoms and renal function，mitigate renal injury，and effectively delay disease progression.